Coherus Oncology (CHRS) Competitors $1.33 +0.02 (+1.53%) Closing price 09/11/2025 04:00 PM EasternExtended Trading$1.32 -0.01 (-0.38%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CHRS vs. OPT, ARVN, OLMA, KOD, ATYR, AQST, ESPR, IVA, RAPP, and CYRXShould you be buying Coherus Oncology stock or one of its competitors? The main competitors of Coherus Oncology include Opthea (OPT), Arvinas (ARVN), Olema Pharmaceuticals (OLMA), Kodiak Sciences (KOD), aTyr Pharma (ATYR), Aquestive Therapeutics (AQST), Esperion Therapeutics (ESPR), Inventiva (IVA), Rapport Therapeutics (RAPP), and CryoPort (CYRX). These companies are all part of the "pharmaceutical products" industry. Coherus Oncology vs. Its Competitors Opthea Arvinas Olema Pharmaceuticals Kodiak Sciences aTyr Pharma Aquestive Therapeutics Esperion Therapeutics Inventiva Rapport Therapeutics CryoPort Coherus Oncology (NASDAQ:CHRS) and Opthea (NASDAQ:OPT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation, media sentiment and institutional ownership. Which has better valuation and earnings, CHRS or OPT? Coherus Oncology has higher revenue and earnings than Opthea. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCoherus Oncology$272.21M0.57$28.51M$1.550.86Opthea$30K19,437.00-$162.79MN/AN/A Do insiders & institutionals have more ownership in CHRS or OPT? 72.8% of Coherus Oncology shares are owned by institutional investors. Comparatively, 56.0% of Opthea shares are owned by institutional investors. 8.1% of Coherus Oncology shares are owned by company insiders. Comparatively, 3.2% of Opthea shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Do analysts prefer CHRS or OPT? Coherus Oncology currently has a consensus price target of $4.51, indicating a potential upside of 239.29%. Opthea has a consensus price target of $1.33, indicating a potential downside of 60.90%. Given Coherus Oncology's stronger consensus rating and higher possible upside, analysts clearly believe Coherus Oncology is more favorable than Opthea.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coherus Oncology 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Opthea 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.17 Is CHRS or OPT more profitable? Coherus Oncology has a net margin of 125.90% compared to Opthea's net margin of 0.00%. Company Net Margins Return on Equity Return on Assets Coherus Oncology125.90% N/A -34.85% Opthea N/A N/A N/A Does the media favor CHRS or OPT? In the previous week, Coherus Oncology had 3 more articles in the media than Opthea. MarketBeat recorded 4 mentions for Coherus Oncology and 1 mentions for Opthea. Opthea's average media sentiment score of 1.89 beat Coherus Oncology's score of 0.48 indicating that Opthea is being referred to more favorably in the news media. Company Overall Sentiment Coherus Oncology Neutral Opthea Very Positive Which has more risk and volatility, CHRS or OPT? Coherus Oncology has a beta of 0.88, meaning that its stock price is 12% less volatile than the S&P 500. Comparatively, Opthea has a beta of 1.17, meaning that its stock price is 17% more volatile than the S&P 500. SummaryCoherus Oncology beats Opthea on 9 of the 14 factors compared between the two stocks. Get Coherus Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for CHRS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CHRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CHRS vs. The Competition Export to ExcelMetricCoherus OncologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$152.26M$3.15B$5.78B$10.07BDividend YieldN/A2.32%5.69%4.62%P/E Ratio0.8621.6074.9726.20Price / Sales0.57297.80472.3091.87Price / Cash4.4945.3337.0859.91Price / Book-1.179.7112.116.28Net Income$28.51M-$53.33M$3.29B$270.85M7 Day Performance3.10%1.04%1.55%3.58%1 Month Performance45.21%9.93%7.83%6.67%1 Year Performance3.10%13.80%61.70%27.73% Coherus Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CHRSCoherus Oncology4.21 of 5 stars$1.33+1.5%$4.51+239.3%+0.0%$152.26M$272.21M0.86330OPTOpthea0.5328 of 5 stars$3.41+7.2%$1.33-60.9%+10.0%$583.10M$30K0.008Positive NewsGap UpHigh Trading VolumeARVNArvinas3.0414 of 5 stars$7.94+1.4%$19.76+148.9%-68.6%$574.86M$263.40M-7.86420Positive NewsOLMAOlema Pharmaceuticals2.8786 of 5 stars$7.58-8.8%$24.00+216.6%-35.2%$570.35MN/A-3.8370News CoverageAnalyst UpgradeGap UpKODKodiak Sciences3.611 of 5 stars$9.79-6.9%$11.75+20.0%+301.6%$555.68MN/A-2.5890ATYRaTyr Pharma2.6194 of 5 stars$5.46-2.7%$23.25+325.8%+178.3%$549.71M$230K-6.8253AQSTAquestive Therapeutics2.2485 of 5 stars$5.01-7.6%$10.29+105.3%+0.0%$540.50M$57.56M-7.16160ESPREsperion Therapeutics4.1364 of 5 stars$2.51-6.3%$7.00+178.9%+60.3%$540.35M$332.31M-5.12200Positive NewsIVAInventiva3.0599 of 5 stars$5.37-3.6%$14.83+176.2%+157.6%$532.84M$9.95M0.00100Short Interest ↑Gap DownRAPPRapport Therapeutics2.7068 of 5 stars$31.47+119.2%$31.00-1.5%+22.7%$524.11MN/A-12.59N/ATrending NewsInsider TradeHigh Trading VolumeCYRXCryoPort3.7896 of 5 stars$10.04-3.0%$12.00+19.5%+21.6%$518.19M$228.38M7.551,186Positive News Related Companies and Tools Related Companies Opthea Alternatives Arvinas Alternatives Olema Pharmaceuticals Alternatives Kodiak Sciences Alternatives aTyr Pharma Alternatives Aquestive Therapeutics Alternatives Esperion Therapeutics Alternatives Inventiva Alternatives Rapport Therapeutics Alternatives CryoPort Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CHRS) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredUrgent: $3,452.50 a Month in Passive "AI Equity Checks"The U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coherus Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Coherus Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CHRS Stock Alerts